Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have received an average rating of "Moderate Buy" from the seven brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $17.00.

Several analysts recently commented on the stock. Chardan Capital raised their price target on shares of Lexeo Therapeutics from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Tuesday, October 7th. Oppenheimer assumed coverage on shares of Lexeo Therapeutics in a report on Thursday, July 31st. They set an "outperform" rating and a $20.00 price target for the company. HC Wainwright raised their price target on shares of Lexeo Therapeutics from $9.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday, October 7th. Weiss Ratings restated a "sell (d-)" rating on shares of Lexeo Therapeutics in a report on Wednesday, October 8th. Finally, Leerink Partners raised their price objective on shares of Lexeo Therapeutics from $9.00 to $20.00 and gave the company an "outperform" rating in a research report on Tuesday, October 7th.

Lexeo Therapeutics Price Performance

Shares of LXEO opened at $8.20 on Tuesday. Lexeo Therapeutics has a one year low of $1.45 and a one year high of $11.72. The company has a 50-day moving average of $5.56 and a two-hundred day moving average of $4.25. The stock has a market cap of $442.80 million, a price-to-earnings ratio of -2.52 and a beta of 1.66.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.04. Analysts anticipate that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Hedge Funds Weigh In On Lexeo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC bought a new position in Lexeo Therapeutics during the first quarter valued at approximately $5,139,000. Palumbo Wealth Management LLC bought a new position in Lexeo Therapeutics during the second quarter valued at approximately $226,000. Nuveen LLC bought a new position in Lexeo Therapeutics during the first quarter valued at approximately $125,000. Ground Swell Capital LLC bought a new position in Lexeo Therapeutics during the first quarter valued at approximately $80,000. Finally, Privium Fund Management B.V. raised its position in Lexeo Therapeutics by 16.0% during the first quarter. Privium Fund Management B.V. now owns 160,198 shares of the company's stock valued at $556,000 after acquiring an additional 22,083 shares in the last quarter. Institutional investors own 60.67% of the company's stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.